Gilead Guides FY Loss of $3.40-$3.75/Shr, First Specific EPS Outlook
GILD sits 25% above its 52-week low of $108.46.
Summary
Gilead provided its first specific full-year loss per share guidance of $3.40 to $3.75, a material update from the prior qualitative net loss outlook. This follows the Q1 10-Q that flagged an $11.5B IPR&D charge from recent acquisitions, including the $3.15B Tubulis deal. The per-share range gives investors a concrete earnings anchor for the first time, likely prompting model revisions. The stock closed at $135.25 before the release.
At the time of this announcement, GILD was trading at $135.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $167.9B. The 52-week trading range was $108.46 to $157.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.